×
Mannatech Net Cash Flow 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Mannatech net cash flow from 2010 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
Mannatech Net Cash Flow 2010-2025 | MTEX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Mannatech net cash flow from 2010 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.6B
Zoetis (ZTS)
$65.1B
Daiichi Sankyo, - (DSNKY)
$45.7B
Takeda Pharmaceutical (TAK)
$45.2B
BeOne Medicines - (ONC)
$33.7B
Sandoz Group AG (SDZNY)
$25B
Summit Therapeutics (SMMT)
$21.6B
Merck (MKKGY)
$16.2B
Shionogi (SGIOY)
$14.9B
United Therapeutics (UTHR)
$13.7B
Neurocrine Biosciences (NBIX)
$12.7B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.8B
Madrigal Pharmaceuticals (MDGL)
$7.5B
Corcept Therapeutics (CORT)
$7.4B
Grifols, S.A (GRFS)
$7.3B
Stevanato Group S.p.A (STVN)
$7B
Ionis Pharmaceuticals (IONS)
$6.9B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.1B
Hypermarcas (HYPMY)
$2.9B
Crinetics Pharmaceuticals (CRNX)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Procaps Group, S.A (PROCF)
$2.5B
NewAmsterdam Pharma (NAMS)
$2.4B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B